SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies, emphasizing its strength and long-term vision, particularly after the CEO departure. Discussions highlight the token as Solana's first ETF, with many proclaiming it as the best ETF ever. The community is focused on accumulation, anticipating a significant move.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community discusses the launch of the $DOJE ETF, with some anticipating significant price movement. Talk centers around potential accumulation strategies and whether the ETF will trigger a major rally, although the launch may be delayed. There's also discussion around Dogecoin's long-term value and comparisons to other cryptocurrencies.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma ($ATYR) is trending as traders discuss upcoming Phase 3 data, with potential for a significant short squeeze. Community talking points include Cantor Fitzgerald's overweight rating, Cantor's reduced price target, and the possibility of leaked data influencing recent price action. The focus remains on the binary event of the trial results and its impact on the company's future.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending amid heated discussions around the political motivations behind a recent tragedy, sparking intense debate within the community.  Users are clashing over affiliations and broader cultural grievances, with some pointing fingers and others calling for unity. The conversation highlights the deep divisions and sensitivities surrounding the symbol and its association with political figures.

Apu, also known as Peepo or Helper, is a pepe-variant that is used to represent a much younger, kinder and more naive anthropomorphic frog. Fed up with low-effort memecoins, more often than not led by deceptive developers, Apu decided to create his own fairly launched, fully transparent coin: $APU – the one and only coin for all frens.

Apu Apustaja 

$APU.X is trending as the community rallies around the meme coin, highlighting its strong 4chan roots and community-driven nature. Conversations mention $APU.X's unique position within the memecoin landscape, with some drawing comparisons to other popular coins and its potential for significant growth. The recent listing on Hyperliquid and a guerilla marketing contest are adding to the buzz.

Grab Holdings Ltd. engages in the provision of millions of people each day to access its driver- and merchant-partners to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending, insurance, wealth management and telemedicine, all through a single “everyday everything” app. The firm operates in food deliveries and mobility and by TPV in the e-wallets segment of financial services in Southeast Asia. It operates across the deliveries, mobility and digital financial services sectors in eight countries namely: Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. The company was founded by Anthony Tan Ping Yeow and Tan Hooi Ling in 2012 and is headquartered in Singapore.

Grab Holdings Limited - Ordinary Shares - Class A

Grab Holdings Limited

Grab Holdings is trending as investors discuss its potential breakout from a long consolidation period, citing bullish technical patterns and upcoming earnings. Community members are pointing to the company's strong presence in Southeast Asia and potential catalysts like a possible GoTo Group deal. Some are also noting institutional accumulation and a positive analyst outlook, contributing to the increased attention on the stock.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks ($ANET) is trending due to positive analyst ratings and price target increases, driven by its strong position in AI-driven networking and data center infrastructure. Community discussions revolve around the stock's recent price action, with some seeing a buying opportunity amid profit-taking, while others express frustration over market manipulation. $ANET's growth potential in the expanding AI networking market remains a key talking point.

The ODP Corp. is a holding company, which engages in the provision of business services and supplies, products, and digital workplace technology solutions. It operates through the following segments: ODP Business Solutions Division, Office Depot Division, and Veyer Division. The ODP Business Solutions Division acts as a B2B distribution solutions provider serving small, medium, and enterprise level companies, including those in the public and education sectors. The Office Depot Division offers retail consumer and small business products and services distributed through a fully integrated omni-channel platform of 869 Office Depot and OfficeMax retail. The Veyer Division consists of supply chain, distribution, procurement, and global sourcing operation, which specializes in B2B and consumer business service delivery, with core competencies in distribution, fulfillment, transportation, global sourcing and purchasing. The company was founded in 1986 and is headquartered in Boca Raton, FL.

ODP Corporation (The)

ODP is trending due to a mix of factors including new share repurchase authorizations and discussion around the potential sale of its consumer business. The company recently reported earnings and detailed a path to unlocking earnings potential with newly realigned business units, which has sparked conversation within the investment community. Community members are also discussing the stock's valuation and technical indicators.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending as the community discusses recent price action and potential accumulation patterns, with some pointing to a 'massive buy spike'. Community members are debating whether this signals the start of a sustained uptrend or another pump and dump, while others highlight the upcoming Goliath Testnet deployment.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement, sparking discussions about the company's future and potential for a short squeeze. The community is closely watching upcoming events, with some anticipating significant price movement. Others are wary of potential dilution and volatility given the low float.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of BioLineRx (BLRX) skyrocketed 32% on Friday after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-new-pilot-phase-data-phase-2-combination">announced</a> positive data from the single-arm pilot phase of its Phase 2 trial evaluating its drug in the treatment of pancreatic cancer.The study is evaluating the company’s Motixafortide, Cemiplimab, and standard-of-care chemotherapies Gemcitabine and Nab-paclitaxel, versus Gemcitabine and Nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. Progression-free means that the patient's disease did not get worse or spread.CEO Philip Serlin said that the data emerging from the pilot phase of the study are “extremely encouraging,” while also noting that pancreatic cancer is the “most challenging” tumor to treat.The company also stated that it now plans to enroll 108 patients in the Phase 2 trial, which will be a randomized study, based on the results of the pilot phase. The company had previously planned to enroll only 30 patients in the study.The trial is planned to be fully enrolled in 2027. While the trial's primary endpoint is progression-free survival (PFS), secondary objectives include safety, response rate, disease control rate, duration of clinical benefit, and overall survival.Following the news, Jones Research upgraded BioLineRx to ‘Buy’ from ‘Hold’ with a $12 price target. With these results, BioLineRx will have additional opportunities to either partner the asset or fund a pivotal trial, assuming favorable Phase II results, the analyst said.On Stocktwits, retail sentiment around BLRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_12_47_05_PM_png_ca2195fcbe.webp" alt="BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits" width="626" height="68"><figcaption>BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/BLRX">BLRX</a> is down by about 50% this year and by about 84% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-eyeing-hiv-drug-rollout-in-low-income-countries-report/ch0ubVvRbuE">Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating

The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.

Equity

Nasdaq-listed shares of BioLineRx (BLRX) traded 4% higher on Tuesday afternoon after the company reported an over 600% year-on-year jump in its first-quarter net income.The Israel-based biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2025-financial-results-and-provides-corporate-update-302465635.html">reported</a> revenues for the three months ended March 31, 2025, of $0.3 million, compared to revenues of $6.9 million in the year-ago period, and below an analyst estimate of $1 million, as per Koyfin data.BioLineRx out-licensed its FDA-approved Aphexda, used in treating a type of cancer called multiple myeloma, to Ayrmid last November and shut its U.S. commercial operations by the year-end.Aphexda, however, generated sales of $1.4 million in the first quarter, providing the company with $0.3 million in royalties.The fall in revenue in the first quarter reflects the company’s change in operation after out-licensing Aphexda, it said.Net income for the quarter ended March 31, 2025, was $5.1 million, compared to $0.7 million for the quarter ended March 31, 2024, and above an estimated net loss of $3 million. The net non-operating income stood at $7.6 million, compared to net non-operating income of $4.5 million in the three months ended March 31, 2024.The company ended the quarter with cash, cash equivalents, and short-term bank deposits of $26.4 million, which it expects to be sufficient through the second half of 2026.CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda."I remain optimistic that we will announce a meaningful transaction this year," he said.On Stocktwits, retail sentiment around BioLineRx rose within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_27_at_1_49_08_PM_png_c44b3d7c0e.webp" alt="BLRX's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 27, 2025 | Source: Stocktwits " width="627" height="65"><figcaption>BLRX's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 27, 2025 | Source: Stocktwits&nbsp;</figcaption></figure><a href="https://stocktwits.com/symbol/BLRX">BLRX stock</a> is down by about 63% this year and nearly 87% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/byd-sued-by-brazil-prosecutors-for-alleged-human-trafficking/ch0V1GJRbra">BYD Sued By Brazil Prosecutors For Alleged Human Trafficking: Retail’s In Wait-And-Watch Mode</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident

CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda. 

BioLineRx Issues Letter to Shareholders

BioLineRx Issues Letter to Shareholders BioLineRx Issues Letter to Shareholders PR Newswire TEL AVIV, Israel, Jan. 21, 2025 - Company outlines strategic long-term vision and financial outlook - TEL...

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares PR Newswire TEL AVIV, Israel...

BioLineRx Announces $10 Million Registered Direct Offering

BioLineRx Announces $10 Million Registered Direct Offering BioLineRx Announces $10 Million Registered Direct Offering PR Newswire TEL AVIV, Israel, Jan. 6, 2025 TEL AVIV, Israel, Jan. 6, 2025...

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on...

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell...

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA (motixafortide) through Gamida Cell Ltd.

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA (motixafortide) through Gamida Cell Ltd. BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to...

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 PR Newswire TEL AVIV, Israel, Nov. 20, 2024 Management to Hold...

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024...

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.36	--	--	N/A
Q2 '25	-$0.35	$0.00	100.00%	BEAT
Q1 '25	-$0.95	$0.00	100.00%	BEAT
Q4 '24	-$0.81	-$0.01	98.76%	BEAT
Q3 '24	-$0.04	$0.00	100.00%	BEAT

BLRX
BioLineRx, Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest BLRX News

BLRX BioLineRx, Ltd.